Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation

In acute myeloid leukemia (AML), mutations of the Fms-like tyrosine kinase 3 receptor (FLT3) and its overexpression are related with hyperleukocytosis, higher risk of relapse, and decrease of both disease-free survival and overall survival. It has been suggested that this phenomenon confers prolifer...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2017-03, Vol.19 (3), p.21-21, Article 21
Main Authors: Best-Aguilera, Carlos, Rodrigo Gómez-Vázquez, O., Elizabeth Guzmán-Hernández, A., Monserrat Rojas-Sotelo, R.
Format: Article
Language:English
Subjects:
Cell Proliferation - drug effects
Disease-Free Survival
fms-Like Tyrosine Kinase 3 - antagonists & inhibitors
fms-Like Tyrosine Kinase 3 - genetics
Humans
Leukemia (A Aguayo
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - pathology
Medicine
Medicine & Public Health
Molecular Targeted Therapy
Mutation
Oncology
Protein Kinase Inhibitors - therapeutic use
Section Editor
Topical Collection on Leukemia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In acute myeloid leukemia (AML), mutations of the Fms-like tyrosine kinase 3 receptor (FLT3) and its overexpression are related with hyperleukocytosis, higher risk of relapse, and decrease of both disease-free survival and overall survival. It has been suggested that this phenomenon confers proliferative and survival advantages to the malignant blast cells. As a consequence, it is an attractive therapeutic target. As the best treatment strategy for mutated FLT3 AML remains to be defined, the addition of FLT3 inhibitor drugs to chemotherapy or to the bone marrow transplant approach has become a growing strategy. With encouraging results, this combination seems to be an attractive option. Relevant data regarding the current treatment trends on mutated FLT3 AML is reviewed here.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-017-0573-x